ironwood pharmaceuticals inc (IRWD) Key Developments
Ironwood Pharmaceuticals, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 12:55 PM
Aug 14 15
Ironwood Pharmaceuticals, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 12:55 PM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Mark G. Currie, Chief Scientific Officer, Senior Vice President and President of Research & Development.
Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S
Aug 5 15
Ironwood Pharmaceuticals, Inc. announced an agreement with Allergan plc for the U.S. co-promotion of VIBERZI™ (eluxadoline), Allergan’s new treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). This arrangement is separate from and complementary to the companies’ ongoing co-development and co-commercialization of LINZESS® (linaclotide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). This collaboration enables Ironwood and Allergan to work together to bring forward two innovative medicines demonstrated to improve the abdominal pain and bowel dysfunction that define IBS-C and IBS-D, two types of IBS that impact nearly 30 million adult Americans. Under the terms of the agreement, Ironwood’s clinical sales specialists will detail VIBERZI to the approximately 25,000 health care practitioners to whom they currently detail LINZESS and Cologuard. LINZESS will remain the first-position product for the Ironwood sales team. Ironwood’s promotional efforts will be compensated based on the volume of calls delivered by Ironwood’s sales force, as well as agreed upon performance metrics. Allergan will be responsible for all other costs relating to the commercialization of VIBERZI. The co-promotion will begin as soon as VIBERZI is commercially available.
Ironwood Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 5 15
Ironwood Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $27.744 million against $6.840 million a year ago. Loss from operations was $42.009 million against $55.119 million a year ago. Net loss was $48.020 million or $0.34 per basic and diluted share against $60.357 million or $0.44 per basic and diluted share a year ago. The company used approximately $26 million of cash for operations as compared to approximately $36 million in the second quarter of 2014.
For the six months, the company reported revenue of $56.676 million against $21.445 million a year ago. Loss from operations was $70.076 million against $99.506 million a year ago. Net loss was $81.242 million or $0.57 per basic and diluted share against $109.983 million or $0.82 per basic and diluted share a year ago.
Ironwood Pharmaceuticals, Inc. Presents at BioPharm America 2015, Sep-15-2015
Jul 30 15
Ironwood Pharmaceuticals, Inc. Presents at BioPharm America 2015, Sep-15-2015 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.
Ironwood Pharmaceuticals, Inc. Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973
Jul 22 15
Ironwood Pharmaceuticals, Inc. announced positive top-line data from a Phase I study of IW-1973, its lead investigational soluble guanylate cyclase (sGC) stimulator. In the study, IW-1973 demonstrated cardiovascular pharmacodynamic effects, extensive tissue distribution, proof of mechanism for sGC stimulation, and a dose range that was well tolerated in healthy volunteers. The totality of clinical and preclinical data generated to date strongly support continued development of IW-1973 as a potential once-daily oral therapy. Ironwood intends to initiate a Phase Ib multiple ascending dose study of IW-1973 in the fourth quarter of 2015. This study will inform the selection of doses and priority indications for the Phase II program, which will focus on areas with the unmet need and optimal path to market. Ironwood intends to initiate at least two Phase II proof of concept studies for IW-1973 in 2016. The randomized, double-blind, placebo-controlled, single ascending dose Phase I study enrolled 46 healthy volunteers. Participants were randomized 3:1 to receive a single dose of IW-1973 or placebo administered via an oral capsule. Top-line clinical data were consistent with preclinical findings and included cardiovascular pharmacodynamic effects, dose-proportional pharmacokinetics, biomarker-based confirmation of target engagement, and evidence of extensive distribution to tissues. No serious adverse events were reported. Reported adverse events were consistent with the mechanism of action. Data from clinical and preclinical studies of IW-1973 are expected to be presented at a future medical conference.